目的:The aim of this study was to assess the effects of nCPAP treatment in CKD with OSA patients.方法:In this study,159 patients with stages 5 CKD were enrolled from January of 2014 to June of 2016.The OSA was diagnosed by polysomnography.The severity of OAS was categorized as none （apnea/hypopnea index,AHI﹤5/h）,mild（5/h≦apnea/hypopnea index,AHI﹤15/h）,or moderate to severe （apnea/hypopnea index,AHI≧15/h）.The declining rate of the estimated GFR （eGFR） was evaluated for over 6 months.87 patients were diagnosed as OSA.49 patients were mild OAS and 30patients were moderate to severe OAS.The associations between the eGFR and patient characteristics were evaluated in those patients.39 patients with OSA （22 patients were mild and 17 patients were moderate to severe） accepted the treatment of nCPAP（more than four hours per night,and more than 70%of nights） for 6 months.结果:Then the declining rate of eGFR was determined in all patients after 6 months.At baseline,our results showedthat age,BMI,mean SaO2%,SaO2<90%monitoring time and AHI were significantly associated with level of eGFRs.The eGFR declined faster in those patients with OSA （excluded those accepted nCPAP treatment） than patients with no OSA per year.The eGFR decline was slowed down in patients with the 12 month treatment of nCAPA,which was significantly effective in the patientswith moderate to severe OAS.结论:In conclusions,nCPAP therapy could ameliorate CKD progression in the patients combined CKD and OSA,especially in CKD patients with moderate and severe OSA.